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ABSTRACT
The coinfection of HIV and hepatitis B virus (HBV) and their vertical transmission constitute a pub-
lic health problem in sub-Saharan countries of Africa. The objectives of this research are: i) identify 
the pregnant women that are coinfected by HIV and HBV at Saint Camille Medical Centre; ii) use 
three antiretroviral drugs (zidovudine, nevirapine and lamivudine) to interrupt the vertical trans-
mission of HIV and HBV from infected mothers; and iii) use the PCR technique to diagnose chil-
dren who are vertically infected by these viruses in order to offer them an early medical assistance. 
At Saint Camille Medical Centre, 115 pregnant women, aged from 19 to 41 years, were diagnosed as 
HIV-positive and, among them, 14 coinfected with HBV. They had at least 32 weeks of amenorrhoea 
and all of them received the HAART, which contained lamivudine. Two to six months after child-
birth, the babies underwent PCR diagnosis for HIV and HBV. The results revealed that, among these 
mothers, 64.4% were housewives, 36.5% were illiterates, and only 1.7% had a university degree. The 
rate of vertical transmission of HIV and HBV was 0.0% (0/115) and 21.4% (3/14), respectively. The 3 
mothers who transmitted the HBV to their children had all HBsAg, HbeAg, and HBV DNA positive. 
An antiretroviral therapy that in addition to zidovudine and nevirapine includes lamivudine could, 
as in the present study, block or reduce the vertical transmission in HIV positive pregnant women 
who are coinfected with HBV.
Keywords: pregnant women, HIV, HBV, MTCT, lamivudine, HAART, Burkina Faso.
[Braz J Infect Dis 2010;14(3):219-224]©Elsevier Editora Ltda.
INTRODUCTION
Burkina Faso, located in the middle of West-
ern Africa, is bounded to the North and West 
by Mali, to the East by Niger, and to the South 
by Ivory Coast, Ghana, Togo, and Benin. It is 
one of the Sub-Saharan African countries that 
are more struck by the HIV/AIDS and HBV 
infection.1,2 Among the modes of infection of 
the Human Immunodefi ciency Virus (HIV) 
and Hepatitis B Virus (HBV), the mother-to-
child vertical transmission (MTCT) is a well-
established fact.34 This transmission is carried 
out in the intrauterine life by mother-foetal mi-
cro-transfusion, during the delivery by contact 
with maternal blood and vaginal secretions, or 
during breast feeding.4,5 
In the tropical zones of Africa in the South of 
the Sahara, HIV/AIDS, by its morbidity and mor-
tality, constitutes a real problem of public health. 
Moreover, HBV, by its endemicity, is the main fac-
tor inﬂ uencing the occurrence of cirrhosis and 
hepatocellular carcinoma at a young age.6,7 While 
in developed countries the prevalence of antigen 
HBs (HBsAg) chronic carriers among pregnant 
women is lower than 1%, under the Tropics this 
prevalence is higher than 10%.8-10
The presence of the antigen HBe (HBeAg) 
is an important risk factor for infectivity. In 
fact, when a mother is HBeAg positive, the risk 
of vertical transmission for the new-born baby 
is 90% with a high risk of chronic infection.11 
The probabilities of vertical transmission are 
also related to the title of HBsAg, anti-HBc 
antibodies, and HBV polymerase activity.12,13 
Nowadays, the life expectancy of HIV posi-
tive patients has increased considerably and 
their quality of life has been improved with the 
use of the new antiretroviral three-therapies. 
Thus, in this context of chronic HIV disease, 
the problem arising from the chronic coinfec-
tion with HBV and HCV14 is becoming impor-
tant. To contribute to the eradication of such 
coinfections at the source, one way would be to 
systematically block the vertical coinfection of 
HIV and HBV.
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This research has the following goals: i) to identify the 
pregnant women coinfected by HIV and HBV in the Medi-
cal Centre of Saint Camille; ii) to prove the effectiveness of 
lamivudine in addition to zidovudine and nevirapine in 
order to reduce the rates of HIV and HBV vertical trans-
mission; iii) to use the technique of PCR at real time to di-
agnose the children infected vertically by these two viruses; 
and iv) to draw the attention of the decision makers on the 
need for protecting the most vulnerable and exposed groups 
(children and newly-born babies) and thus contribute to a 
better international orientation of the fi ght against mother-
to-child co-transmission of HIV and HBV.
 
MATERIAL AND METHODS
Samples
From January 7, 2007, to April 30, 2009, 2130 pregnant 
women with less than 32 weeks of amenorrhoea and aged 
from 18 to 41 years old (average age of 26.64 ± 4.75), have 
freely agreed after counselling to get tested for HIV and to 
follow the protocol of the Maternal to Child Transmission 
of HIV (MTCT-HIV), if they are found to be HIV positive. 
Among these women, 115 (5.4%) were HIV seropositive and 
also agreed to get tested for HBV. 
Blood taking
After signing informed consent, 10 mL of blood samples 
was collected from pregnant women in 2 tubes contain-
ing EDTA. The fi rst tube was used for HIV ELISA test and 
CD4+ count, while the second tube was centrifuged at 3000 
rpm for 10 min for HIV EIA and HBV ELISA and for virus 
loading test. After the consent of the HIV positive parents, 5 
ml of blood was taken from their children at the age of 4-6 
months. Their plasma was kept at -80° C until the HIV and 
HBV RT-PCR test were performed. 
Test
The serological screening for HIV was performed by sequen-
tially using two rapid tests, i.e., Determine® and Genius-II®, 
used to detect both HIV-1 and HIV-2, as previously de-
scribed (Koblavi-Dème et al., 2001).15 A third test was used 
in all those cases in which the two rapid tests had unmatched 
results. In such cases the samples were tested with EIA (En-
zyme Immuno Assay), using the Abbott IMX System (Abbot 
Laboratories, N. Chicago, IL, USA), in order to confi rm or 
exclude HIV infection. CD4+ T cell count was enumerated 
by FACS Count (Becton Dickinson, San Jose, CA, USA) and 
the virus load was determined using the LCX system (Abbot 
Laboratories, North Chicago, IL). 
The mother who result positive for HIV were tested for 
HBV markers (HBsAg; HBeAg; HBsAb; HBcAb; and HBe-
Ab) using the speedy kit (Hepatitis B Virus Combo Device 
Test, House Laboratories Barge, Inc, USA). 
The viral load test for HIV and HBV were carried out by re-
al-time PCR system (Applied System) by using both the kit Di-
rect HIV-1 RNA of Diatech (Italy) and the TM quantifi cation 
kit for Hepatitis B virus (Hoffmann La Roche A, Germany).
For the HIV qualitative RT-PCR test: total RNA was ob-
tained by using the Dia Tech RNA extraction kit and Qiagen 
columns (Qiagen GmbH, Hilden, Germany). Samples were 
amplifi ed by 1 cycle under the following conditions: 42° C 60 
min, 94° C 5 min. The 50 cycles under the following condi-
tions: 93° C for 30s, 60° C for 30s, 72° C for 30s, 72° C for 15 
min for extension fi nal. Electrophoresis was performed on a 
3% agarose gel in 1X TBE BUFFER (40 mM Tris-Borate, 1 
mM EDTA, pH 8.0) for 1 hour at a constant voltage of 120 V. 
The fragments were visualised after staining with Ethidium 
bromide and photographed under UV light.
We used primer design 2X Precision TM MasterMix for 
HBV DNA amplifi cation (Hoffmann-LaRoche Inc.). DNA 
amplifi cation Protocol: UNG treatment 15 mins 37° C, En-
zyme Activation 10 mins 95° C, and the 50 cycles under the 
following conditions: 95° C for 10s, 60° C for 60s, 72° C for 
15 min for fi nal extension.
A second MTCT-HIV program (2006-2010) was adopt-
ed in 2006, but its execution was not immediate in all the 
country. It was proposed the use of three molecules (zido-
vudine, nevirapine and lamivudine) for HIV/HBV infected 
mother and two molecules (zidovudine and névirapine) for 
the newborn babies. These women freely agreed to answer 
a questionnaire that we subjected to them referring to their 
school level, their function in the civil service, the number of 
living children they have, the number of deceased children, 
and the number of miscarriages they had before.
Ethical committee 
The Ethic Committee of Saint Camille Medical Centre made 
sure that each person provided an informed consent before 
blood was taken for this study.
Statistical analysis
Demographic and clinical profi les were recorded on com-
puter fi les and analyzed by standard software SPSS-10 and 
EpiInfo-6. Statistical signifi cance was set at p < 0.05.
 
RESULTS
In the MTCT-HIV program, 2130 pregnant women under-
went voluntarily HIV testing. They represent 56% of those 
who were offered counselling and testing. All pregnant 
women who underwent the test came back for results and 
post test counselling. 115/2130 (5.4%) HIV seropositive 
pregnant women were found; 112/115 (97.4%) were infect-
ed with HIV-1 and 3/115 (2.6%) were infected with HIV-2 
(Table 1). The average age between HIV seropositive women 
(28.1 ± 4.3) and seronegative (25.3 ± 5.2) was signifi cantly 
different: p < 0.001.
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Table 2 shows the information on the level of school 
training, occupation and maternity of HIV seropositive 
women distributed according to the age. We note that 36.5% 
of them were illiterate and only 1.7% went to university. The 
majority, due to their low education is very little integrated 
into public service (6.1%). They are basically housewives 
(64.4%) and business women (29.5%). Among them, 
many had several miscarriages during their preceding 
pregnancies (1.6 ± 1.1). In Table 3 are shown the results 
of the biological analyses of the women and their chil-
dren according to the mothers’ age groups. It shows a rate 
of prevalence of 12.2% for HBV among HIV seropositive 
pregnant women and a rate of vertical transmission of 
2.6% for HBV. The test of RT-PCR for HIV showed a rate 
of vertical transmission of 0.0% for children born from 
HIV positive mothers. 
Table 1. Results of the HIV test for 2130 pregnant women screened for the first time in Ouagadougou
                                    2130 serologic test for HIV                               Standard HIV in seropositive subjects 
  HIV- HIV+ HIV/1  HIV/2 
n  2015  115 112 3 
%  94.6%  5.4%  97.4%  2.6% 
Age  25.3 ± 5.3 28.1 ± 4.3 27.8 ± 5.4 32.1 ± 2.4
Age HIV-  HIV+ p < 0.001; Age HIV/1  HIV/2 p = 0.173
Table 3. Results of the biological tests for women and children according to the mothers’ age
                                                          Mothers                                  Children
Age years Numbers ELISA HBV- ELISA HBV+ HIV RT-PCR+ ELISA HBV+
x < 28 43 37/43 6/43 0/43 2/43
years* 37.4% 86.1% 13.9% 0.0% 4.7%
28 to 35 62 55/62 7/62 0/6 1/62
yearso 53.9% 88.7% 11.3% 0.0% 1.6%
x > 35 10 9/10 1/10 0/10 0/10
years^ 8.7% 90% 10.0% 0.0% 0.0%
Total 115 101/115 14/115 0/115 3/115
 100% 87.8% 12.2% 0.0% 2.6%
HBV+ : x2 : * ° p = 0.684;  x2 : * ^ p = 0.853; x2 : ° ^ p = 0.673
Table 2. Information on school training, occupation, and maternity of HIV seropositive women
                    School training of the  Occupation of the Number of children alive,
                   HIV seropositive women HIV sepositive died, and abortions 
  positive women
Age Numbers Illiterates PSC PSFC BAC University Housewives Commercial Civils Number of Number of Number of
group          servant  children children abortions
(years)          alive  dead 
x < 28 43 16/43 15/43 8/43 3/43 1/43 32/43 9/43 2/43 1.79 (0–4) 0.44 (0–2) 0.30 (0–1)
years  37.2% 34.9% 18.6% 7.0% 2.3% 74.4% 20.9% 4.6% 
28-35  62 22/62 21/62 13/62 6/62 0/62 38/62 19/62 5/62 2.29 (1–5) 0.87 (0–4) 0.66 (0–4)
  35.5% 33.9% 21.0% 9.7% 0.0% 61.3% 30.6% 8.1%   
x > 35 10 4/10 3/10 2/10 0/10 1/10 4/10 6/10 0/10 2.33 (1–4) 0.88 (0–3) 0.88 (0– 3)
  40.0% 30.0% 20.0% 0.0% 10.0% 40.0% 60.0% 0.0% 
Total 115 42/115 39/115 23/115 9/115 2/115 74 34 7 2.11 (0–5) 0.69 (0–2)  0.52 (0–4) 
  36.5% 33.9%  20.0%  7.8%  1.7%  64.4% 29.5% 6.1%
PSC = Primary school certificate
PSFC = Patent studies of the first cycle
BAC = Bachelor
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Table 4 shows the rate of the CD4, the viral load of HIV-
RNA and HBV-DNA in HIV seropositive women, and the 
prevalence of the vertical transmission for these viruses ac-
cording to the serologic status of the mothers. Concerning 
the serology of the HBV, there is no statistically signifi cant 
difference among the ages of mothers (p = 0.66), rate of the 
CD4 (p = 0.13), viral load of HIV (p = 0.46), and the ages of 
children (p = 0.78).
At the level of Table 5, the markers of line A indicate the 
type of acute hepatitis B in the children. According to the 
markers of lines B and C, they respectively present inactive 
and cured hepatitis. These results demonstrate that the vertical 
transmission of HBV in the three children occurred because 
the mothers have: HBV DNA, HBsAg, and HBeAg markers. 
DISCUSSION
In our program of prevention of mother-to-child transmis-
sion (MTCT), 2130 pregnant women accepted voluntarily the 
test of HIV. We found 115/2130 (5.4%) HIV positive pregnant 
women; 112/115 (97.4%) for HIV-1 and 3/115 (2.6%) for 
HIV-2 (Table 1); however, we did not identify in our study any 
coinfection of HIV-1 with HIV-2. By considering the averages 
of ages between HIV positive (28.1 ± 4.3) and negative (25.3 
± 5.3) women, we fi nd a very signifi cant statistical difference 
(p < 0.0001), which demonstrate that something is changing 
in the HIV epidemiology in Burkina Faso.
The effectiveness of HAART (zidovudine, nevirapine and 
lamivudine) in the prevention of vertical transmission of HIV 
was confi rmed by several authors.1,16,17
The results obtained in this study show that the MTCT-
HIV is feasible in Saint Camille Medical Centre in Ouaga-
dougou (CMSC) and in all the territory of Burkina Faso. In 
fact, in our present research, the rate of vertical transmis-
sion of HIV is 0/115 (0.0%) (Table 3), which is very differ-
ent from those of Simpore et al., (2006)18 and of Deschamps 
et al. (2009),19 which respectively presented percentages of 
10.4% and 9.2% of mother-to-child transmission of HIV. 
With regard to serologic status of HBV for mothers, on 115 
HIV positive women, 14 (that is to say 12.2%) were positive 
for HBsAg. This rate of prevalence that we found is defi -
nitely higher than those obtained respectively by Sall Diallo 
et al. (2004)20 in Senegal (3.18%), Mahboob et al. (2007)21 
in Pakistan (3.5%), Rivera-Lopez et al. (2004)22 in Mexico 
(1.22%), Tiruneh et al. (2008)23 in Ethiopia (7.3%); and 
Jain et al. (2009)24 in India (9.9%). However, similar rates 
Table 4. The count/mm3 of CD4+, the viral load of HIV/mL and the HBV/mL of the women and the prevalence 
of vertical transmission according to the serologic statutes of the mothers
                              Mothers    Children
HIV+ n Age: years CD4+/mm3 HIV copies/mL  HBVcopies/mL Age: months PCR HIV ELISA HBV
HBV+* 14 30 (24–37) 381.6  Median: 103,8 Median: 3128,0 4.67 0/14 3/14
   ± 117.8 Range: 14752,0 Range: 14750,0 (4-6)  21.4%
HBV–o 101 30.03 470.2 Median: 7457,0  4.89 0/101 0/101
  (19–39) ± 214.3 Range: 251722,0  (2-9)  0.0%
Total 115 19 459 Median: 5549,3  4.88 0/115 3/115 
  (19–39) ± 206.7 Range: 251722,0   (2-9)   2.6%
    X2 :  X2 :    X2 : 
  *  o *  o   *  o
  p = 0.66  p = 0.13   p = 0.78    
Table 5. Markers of hepatitis B virus in mothers and vertical transmission of the virus
 Markers   HBV- HBsAg HBeAg HBsAb HBeAb HBcAb Vertical HBV
 of HBV in  DNA       transmission
 mother HIV+
 A 5 + + + - - + 3
 B 2 - + - - + - 0
 C 7 - - - - - + 0
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were obtained by Ilboudo et al. (2002)25 in Ouagadougou 
(12.04%), as well as by Simpore et al. (2006)18 in Ouaga-
dougou (11.6%), Ilboudo et al. (2007)10 in Saint Camille 
Medical Centre in Ouagadougou (10.4%), and Otegbayo et al. 
(2008)26 in Nigeria (11.9%). Our results are on the other hand 
lower than those of Balan et al. (1998)27 in Romania (36.7%), 
Lukhwareni et al. (2009)28 in South Africa (40.6%), and Nagu 
et al. (2008)14 in Tanzania (17.3%). These differences in rate 
of prevalence show that hepatitis B infection constitutes a 
true problem of world public health in Sub-Saharan Africa. 
Consequently, an adequate instrument of prevention and 
care should be implemented in order to eradicate this plague, 
which affects these people without discrimination. 
Among 14 HIV positive pregnant women coinfected 
with HBV, by observing the viral markers, we see that 7/14 
(50.0%) women were cured from hepatitis B; 2/14 (14.3%) 
were affected by chronic hepatitis B, and 5/14 (35.7%) had 
at the moment acute hepatitis because they were at the 
same time carrying HBsAg, HBeAg, HBcAb, and viral HBV 
DNA positive. Lamivudine (3TC), the oldest nucleoside in-
hibitor of HBV polymerase, is also effective on the reverse 
transcriptase of HIV, when used in dose of 100 mg a day 
for treatment of hepatitis B (in opposition to 300 mg a day 
for treatment of HIV).
Under 3TC (lamivudine or Zeffi x®, Epivir®), the HBV 
DNA quickly drops.29 Thus, lamivudine must be taken into 
account as an important drug for treatment of people coin-
fected by HIV/HBV. In our study, which include lamivudine 
into the antiretroviral three-therapy, 7/14 of the HBV posi-
tive women had undetectable viral load, while 5/14 had a 
high viremy (median : 3128 copies/mL).In a study of Leung 
et al, 2001, after 3 years of continuous treatment with lami-
vudine (100 mg daily), 40% (23 of 58) of patients achieved 
HBeAg seroconversion, and median serum HBV-DNA con-
centrations were below the level of detection; moreover, the 
median ALT concentrations were within the normal range 
throughout 3 years of treatment. Lamivudine was well toler-
ated during 3 years of therapy. The authors concluded that 
in Chinese patients with chronic hepatitis B an enhanced se-
roconversion rates with extended lamivudine treatment was 
reached. After 4 years of treatment with lamivudine, a lami-
vudine resistance appeared in 57% of the patients.30 Among 
patients coinfected by the HIV, the appearance of this resist-
ance occurred even earlier, only after 2 years 86% showed 
HBV DNA suppression.31 In this study lamivudine (300 
mg/d) was effective for the inhibition of HBV replication in 
HIV-infected patients. However, emergence of lamivudine-
resistant HBV occurred in 20% of patients per year.
Among these fi ve mothers having acute hepatitis B with high 
viremy, three vertically transmitted the virus of hepatitis B to their 
children (21.4%) (Table 4). The activation of the viral replication 
during the third quarter of pregnancy presents an important risk 
of 80% to 90% of viral transmission to the child.32 
The vertical HBV transmission rate that we found (21.4%) 
is defi nitely higher than those obtained respectively by Wise-
man et al. (2009)33 in Australia (3.0%), and by Lima and Viana 
(2009)34 in Brazil (1.0%). However, similar rates were obtained 
by Ilboudo et al. (2002)25 in Ouagadougou (25.0%); Koedijk 
et al. (2007)35 report in Netherland that 40% of chronic HBV 
infections were transmitted from mother to child in an area 
not endemic for HIV, but we do not know what happen in 
Burkina Faso. If we add the absence of a pre-partum prepara-
tion, the possibility of a perinatal transmission of HBV is high 
through narrow contact between mother and child, through 
breast feeding or blood contamination with cuts at the breast. 
Since it is evident that the vertical transmission of HBV is 
very high in countries where HBV infection is endemic, the 
needs for effective preventive measures became necessary. 
Even though from 2002, 110 countries had adopted HB im-
munization of all infants as an integral part of the national 
immunization schedule, it should be important to have the 
highest priority in some countries. Then, hepatitis B vaccina-
tion of target groups seems to be a pressing need in countries, 
like Burkina Faso, with a high prevalence of hepatitis B. The 
HBV vaccination represents the more effective instrument 
to prevent mother to child transmission of HBV and the de-
velopment of hepatocellular carcinoma at an early age. The 
experiment conducted in Taiwan showed that this is possible 
with the use of vaccination strategy.36
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